PDCD1 and melanoma: The MASTERKEY-115 trial was a phase II, open-label, multicenter trial that evaluated the combination of T-VEC and pembrolizumab in patients with advanced melanoma in whom the melanoma was refractory to anti-programmed cell death protein-1 (PD-1) inhibitors [69].